TELIX Pharmaceuticals Ltd (AU:TLX) — Market Cap & Net Worth

$3.27 Billion USD · AU$4.62 Billion AUD · Rank #4665

Market Cap & Net Worth: TELIX Pharmaceuticals Ltd (TLX)

TELIX Pharmaceuticals Ltd (AU:TLX) has a market capitalization of $3.27 Billion (AU$4.62 Billion) as of September 16, 2026. Listed on the AU stock exchange, this Australia-based company holds position #4665 globally and #114 in its home market, demonstrating a 9.23% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying TELIX Pharmaceuticals Ltd's stock price AU$17.75 by its total outstanding shares 334724485 (334.72 Million). Also see TELIX Pharmaceuticals Ltd balance sheet assets for a full breakdown of the balance sheet.

TELIX Pharmaceuticals Ltd Market Cap History: 2017 to 2026

TELIX Pharmaceuticals Ltd's market capitalization history from 2017 to 2026. Data shows growth from $146.84 Million to $4.20 Billion (42.62% CAGR). Also see TLX cash generation efficiency for how efficiently the company converts equity into cash flow.

Index Memberships

TELIX Pharmaceuticals Ltd is a constituent of 6 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
Australia All Ordinaries AORD	$1.95 Trillion	0.17%	#97 of 495
S&P/ASX All Australian 200 AXAT	$1.87 Trillion	0.18%	#94 of 200
S&P/ASX 200 AXJO	$1.83 Trillion	0.18%	#90 of 200
S&P/ASX 200 Accumulated AXJOA	$1.83 Trillion	0.18%	#90 of 200
S&P/ASX 300 AXKO	$2.12 Trillion	0.15%	#102 of 300
ASX Small Ordinaries AXSO	$290.30 Billion	1.13%	#24 of 200

Weight: TELIX Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

TELIX Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how TELIX Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check TELIX Pharmaceuticals Ltd stock quote for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

7.44x

TELIX Pharmaceuticals Ltd's market cap is 7.44 times its annual revenue

Industry average: 3887.03x Lower than industry average

Latest Price to Earnings (P/E) Ratio

116.76x

TELIX Pharmaceuticals Ltd's market cap is 116.76 times its annual earnings

Industry average: 1.67x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2017	$146.84 Million	$403.47K	-$6.38 Million	363.95x	N/A
2018	$153.95 Million	$195.14K	-$13.83 Million	788.89x	N/A
2019	$367.10 Million	$3.48 Million	-$27.87 Million	105.34x	N/A
2020	$895.25 Million	$5.21 Million	-$44.89 Million	171.73x	N/A
2021	$1.84 Billion	$7.60 Million	-$80.51 Million	241.64x	N/A
2022	$1.72 Billion	$160.10 Million	-$104.08 Million	10.75x	N/A
2023	$2.39 Billion	$502.55 Million	$5.21 Million	4.75x	458.13x
2024	$5.83 Billion	$783.21 Million	$49.92 Million	7.44x	116.76x

Competitor Companies of TLX by Market Capitalization

Companies near TELIX Pharmaceuticals Ltd in the global market cap rankings as of September 16, 2026. Review TLX tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.

Key companies related to TELIX Pharmaceuticals Ltd by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#186	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$130.44 Billion	$514.63
#353	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$78.29 Billion	$774.11
#457	CSL Ltd	AU:CSL	$59.82 Billion	AU$174.26
#506	Moderna Inc	NASDAQ:MRNA	$54.14 Billion	$143.77

TELIX Pharmaceuticals Ltd Historical Marketcap From 2017 to 2026

Between 2017 and today, TELIX Pharmaceuticals Ltd's market cap moved from $146.84 Million to $ 4.20 Billion, with a yearly change of 42.62%.

Year	Market Cap	Change (%)
2026	AU$4.20 Billion	+58.48%
2025	AU$2.65 Billion	-54.49%
2024	AU$5.83 Billion	+144.15%
2023	AU$2.39 Billion	+38.65%
2022	AU$1.72 Billion	-6.19%
2021	AU$1.84 Billion	+105.03%
2020	AU$895.25 Million	+143.87%
2019	AU$367.10 Million	+138.46%
2018	AU$153.95 Million	+4.84%
2017	AU$146.84 Million	--

End of Day Market Cap According to Different Sources

On Sep 16th, 2026 the market cap of TELIX Pharmaceuticals Ltd was reported to be:

Source	Market Cap
Yahoo Finance	$3.27 Billion USD
MoneyControl	$3.27 Billion USD
MarketWatch	$3.27 Billion USD
marketcap.company	$3.27 Billion USD
Reuters	$3.27 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$4.20 Billion

AU$5.94 Billion AUD

Market Cap Rank

#4665 Global

#114 in Australia

Share Price

AU$17.75

Change (1 day)

+8.63%

52-Week Range

AU$8.63 - AU$17.75

All Time High

AU$31.14